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Abstract: Papua New Guinea (PNG) has a high burden of tuberculosis (TB), including drug-
resistant TB (DR-TB). DR-TB has been identified in patients in Western Province, although there has 
been limited study outside the provincial capital of Daru. This study focuses on the Balimo region 
of Western Province, aiming to identify the proportion of DR-TB, and characterise Mycobacterium 
tuberculosis (MTB) drug resistance-associated gene mutations. Sputum samples were investigated 
for MTB infection using published molecular methods. DNA from MTB-positive samples was 
amplified and sequenced, targeting the rpoB and katG genes to identify mutations associated with 
rifampicin and isoniazid resistance respectively. A total of 240 sputum samples were collected at 
Balimo District Hospital (BDH). Of these, 86 were classified as positive based on the results of the 
molecular assays. For samples where rpoB sequencing was successful, 10.0% (5/50, 95% CI 4.4–21.4%) 
were considered rifampicin-resistant through detection of drug resistance-associated mutations. We 
have identified high rates of presumptive DR-TB in the Balimo region of Western Province, PNG. 
These results emphasise the importance of further surveillance, and strengthening of diagnostic and 
treatment services at BDH and throughout Western Province, to facilitate detection and treatment 
of DR-TB, and limit transmission in this setting. 
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1. Introduction 
Papua New Guinea (PNG) is considered to have a high burden of tuberculosis (TB) and drug-
resistant TB (DR-TB) [1]. In 2017, the estimated incidence of TB was 432 cases per 100,000 people 
nationally, while in 2016 the case notification rate for Western Province was 674 per 100,000 people 
[1,2]. Despite the high burden of TB, HIV is not considered to be a main driver of TB in Western 
Province [3]. In 2017, the national proportion of DR-TB was 3.4% of newly diagnosed TB cases, and 
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26% of previously treated cases, with this proportion including both rifampicin (RIF)-resistant TB 
(RR-TB) and multidrug-resistant TB (MDR-TB) (resistance to both RIF and isoniazid (INH)) [1]. 
Studies undertaken in PNG have identified MDR-TB at sites in Eastern Highlands, Gulf, Madang, 
Milne Bay, Morobe, and Western provinces, and the National Capital District [4–8]. At Daru Hospital 
in the provincial capital of Western Province, MDR-TB has been reported in 34.2% of new and 
previously treated cases, and extensively drug-resistant TB (MDR-TB with additional 
fluoroquinolone and second-line injectable antibiotic resistance) has also been described [3,4,9–13]. 
Other studies have found MDR-TB in 25% of Western Province-based TB patients presenting at 
Australian health clinics in the Torres Strait [14,15]. However, no previous research has investigated 
DR-TB in the Middle Fly District of Western Province, and the geographic origin of DR-TB patient 
samples referred to Daru Hospital (the referral hospital for DR-TB in the province) has not been 
reported. 
Phenotypic drug susceptibility testing (DST) of Mycobacterium tuberculosis (MTB) bacilli isolated 
and cultured from patient clinical samples serves as a reference standard for the diagnosis of DR-TB 
[16]. However, culture-independent molecular methods have advantages over DST due to rapid 
turnaround time, and the ability to be used outside high-containment laboratories. 
The molecular basis of RIF resistance has been well-characterised, with 96% of this resistance 
associated with mutations in an 81-base-pair (bp) hypervariable RIF-resistance determining region 
(RRDR) in the rpoB gene [17,18]. In addition, resistance to INH has been associated with mutations in 
the katG and inhA genes [17,19]. Because a large proportion of RIF-resistant strains have concomitant 
INH resistance, molecular detection of RIF resistance is often used as an early indicator of MDR-TB 
before phenotypic susceptibilities are available, or in countries where DST is not routinely available 
[20]. However, the pattern and frequency of mutations in the rpoB and katG genes in MTB clinical 
isolates have significant geographic variability [21,22]. As a result, techniques that focus only on rpoB, 
such as the World Health Organization (WHO)-recommended Xpert MTB/RIF (Cepheid, USA), may 
overestimate MDR-TB, especially if the local prevalence of RR-TB is unknown. Therefore, an 
approach that can identify both rpoB and katG mutations is more likely to differentiate RR-TB, MDR-
TB, and strains in which MDR-TB is likely to develop (pre-MDR-TB) [23]. 
The Balimo region in the Middle Fly District of Western Province is known to have a high burden 
of TB [24], with limited diagnostic facilities and smear microscopy being the only laboratory-based 
method of TB diagnosis available at Balimo District Hospital (BDH). Given the TB epidemic in 
Western Province, combined with limited data from areas outside the provincial capital, the aim of 
this study was to characterise the extent and type of molecular DR-TB in the remote Balimo region. 
As a preliminary study into DR-TB in this region, where techniques such as the Xpert MTB/RIF are 
not available, we used a pragmatic approach focused on the characterisation of RIF and INH 
resistance, based on mutations in the rpoB and katG genes. We characterised molecular evidence of 
resistance using DNA extracted directly from sputum samples collected at BDH. This study furthers 
understanding of the burden of DR-TB in Western Province. 
2. Study Population and Methods 
2.1. Study Setting 
Balimo is a town of approximately 4400 people and is the urban centre of the Gogodala Rural 
local level government area in the Middle Fly District of Western Province [25]. Numerous small 
villages make up the Gogodala region, with a population of approximately 33,000 people [25]. The 
region is geographically remote with limited road networks, and travel is primarily by boat or by 
foot. Income is limited, with most people having subsistence-based livelihoods. 
The primary health facility serving the region is BDH. However, the hospital has been without 
a physician for many years, and staffed by health extension officers and nurses. At the hospital, 
diagnosis of TB relies on clinical presentation and smear microscopy results, and is based on the PNG 
National Tuberculosis Management Protocol [24,26,27]. The hospital laboratory does not have the 
capacity for culture or Xpert MTB/RIF-based diagnosis of TB. Patients can be commenced on 
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treatment for drug-susceptible TB, while presumptive DR-TB cases must be referred to Daru Hospital. 
For this study, sputum samples were collected from presumptive TB patients as part of routine 
passive case detection activities at BDH. Associated demographic and clinical data were obtained 
from the BDH laboratory register, however information about the TB treatment history of patients 
was not available from this register. 
2.2. Initial Collection and Preparation of Samples 
Sputum samples were collected during the period from April 2016 to June 2017, as part of 
ongoing passive case detection of TB as per the BDH clinical procedures. A total of 240 samples were 
provided on a convenience sampling basis for this study. Processed sputum (n = 213) was prepared 
at the BDH laboratory, using decontamination and concentration procedures according to the 
modified Petroff’s method [28,29], and stored at −20 °C. Following processing, sputum was smeared 
onto microscope slides, and examined for the presence of acid-fast bacilli using Ziehl-Neelsen (ZN) 
staining. Fresh sputum samples (n = 27) were collected in the few days prior to transfer of the samples 
to Townsville. For this reason, the fresh sputum samples could not be processed at BDH as usual, 
and instead were decontaminated and concentrated at James Cook University, Townsville, following 
the same procedure used at BDH. 
2.3. Preparation of DNA Template 
Approximately 100–150 µL of each decontaminated sputum was transferred to a 2 mL tube and 
heat inactivated at 80 °C in a thermal block for 1 h. Sputum was then centrifuged at 3,000 g for 15 min, 
and supernatant removed. A volume of 1 mL of a 4 M guanidine isothiocyanate (GIT) solution was 
added to each tube, and incubated overnight at 37 °C. Samples were then centrifuged at 13,000 rpm 
for 10 min, and supernatant removed. 
Following inactivation, DNA was extracted using the High Pure PCR Template Preparation Kit 
(Roche Diagnostics, Germany). The spun pellets were resuspended in 200 µL of tissue lysis buffer, 
and 40 µL of proteinase K solution, and incubated overnight at 55 °C, or until all sediment was 
dissolved. Subsequent steps were performed according to the manufacturer’s instructions. Extracted 
DNA was stored at −80 °C until use. 
2.4. Confirmation of MTBC Infection 
Two TaqMan real-time polymerase chain reaction (qPCR) assays were used to confirm the 
presence of the Mycobacterium species (IS6110 assay) or M. tuberculosis complex (MTBC) (senX3-regX3 
assay) in the DNA extracts, according to published protocols [30]. While the senX3-regX3 intergenic 
region is specific to the MTBC, IS6110 is present in most strains of M. tuberculosis, but has also been 
identified in other species of Mycobacterium, including non-tuberculous mycobacteria (NTM). Both 
targets were used because the IS6110 assay, which targets a multicopy element, is more sensitive than 
the senX3-regX3 assay, which targets a single copy gene [30]. 
Each qPCR reaction (20 µL) contained 1X GoTaq Probe qPCR Master Mix (Promega, Madison, 
USA), 0.8 µM each of forward and reverse primer, 0.1 µM of probe, and 2 µL of DNA template. The 
positive control used MTB H37Rv (GenBank: AL123456.3). Cycling parameters are shown in Table 1. 
qPCR assays were carried out on a Rotor-Gene Q6000 (QIAGEN, Hilden, Germany). 
Each sample was assayed in duplicate for the IS6110 qPCR, with a triplicate assay for discordant 
results, and assayed once for the senX3-regX3 qPCR. A sample was considered reactive if the cycle 
threshold (Cq) was less than 40 cycles. Samples with duplicate reactivity of the IS6110 assay as well 
as reactivity of the senX3-regX3 assay were considered MTB-positive, while samples with duplicate 
reactivity of the IS6110 assay only were classified as MTBC/NTM. In PNG, only a small number of 
NTM strains have been identified, and they are likely to have limited influence in the context of our 
study [4,26,31]. However, because the possibility of rare NTM in the IS6110-positive samples cannot 
be completely excluded, we have used the ‘MTBC/NTM’ classification for accuracy. 
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Table 1. Cycling parameters for the real-time PCR (qPCR) and conventional PCR (rpoB and katG) 
assays. 
Assay No. Cycles Thermal Conditions 
IS6110 / senX3-regX3 
1 95 °C for 2 min 
45 
95°C for 5 s 
60°C for 15 s 
rpoB 
1 94°C for 2 min 
35 
94°C for 30 s 
58°C for 30 s 
72°C for 40 s 
1 72°C for 5 min 
katG 
1 94°C for 2 min 
40 
94°C for 30 s 
60°C for 30 s 
72°C for 60 s 
1 72°C for 5 min 
C: Celsius; No.: number. 
2.5. rpoB and katG Mutation Analysis 
Targeted PCR was used to identify mutations in the rpoB and katG genes in DNA extracted from 
the TB clinical samples. Each PCR reaction (25 µL) contained 1X GoTaq G2 Green Master Mix 
(Promega, Madison, USA), 0.5 (rpoB) or 0.8 (katG) µM each of forward and reverse primer, and 2 µL 
of DNA template. The positive control used MTB H37Rv (GenBank: AL123456.3). The rpoB and katG 
primer sets have been described elsewhere [8], with the published conditions optimised in-house for 
each protocol, as described in Table 1. The PCR assays were undertaken on BIOER GeneTouch and 
Kyratec SuperCycler Trinity PCR machines. Amplicons showing single clear bands after agarose gel 
electrophoresis were sequenced in both directions (Macrogen, Korea). Sequence chromatograms 
were analysed using Geneious R10 (Biomatters Limited, Auckland, New Zealand), with the 
consensus sequences of each sample compared to the MTB H37Rv reference sequence (GenBank: 
AL123456.3). The numbering system used in the results is according to that described previously for 
MTB H37Rv [32]. 
2.6. Analysis of Duplicate and Repeat Samples 
Duplicate samples were excluded from the analyses for four patients. Three patients had both 
new (initial TB investigation) and follow-up (post-treatment commencement) samples collected and 
included in the analysis. Follow-up samples were collected at different time-points, ranging from two 
to four months following treatment commencement. 
2.7. Ethics Approval 
The study was undertaken in collaboration with BDH, and received approval locally from the 
Middle Fly District Health Service, and the Evangelical Church of PNG Health Service. Human 
research ethics approval was received from the James Cook University Human Research Ethics 
Committee (Ethics Approval Number H6432) and the PNG Medical Research Advisory Committee 
(MRAC No. 17.02). 
3. Results 
3.1. Demographic Information and Detection of MTB Infection 
Overall, 240 sputum samples were collected, with 236 samples from 233 patients analysed based 
on the exclusion criteria described previously (see Methods). Patient distributions by age and sex are 
shown in Table 2. Sample status at time of collection, and smear microscopy results for new samples 
only, are shown in Table 3. 
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Table 2. Demographics of presumptive tuberculosis (TB) patients in the Balimo region of Papua New 
Guinea (PNG), from samples collected as part of routine passive case detection activities at Balimo 
District Hospital (BDH). Out of 240 samples initially collected, a total of 236 samples originating from 
233 patients were analysed, as three patients had both new and follow-up samples collected, and four 
samples were duplicates. 
Category - n (%) 
Sex 
Female 123 (53) 
Male 109 (47) 
Unknown 1 (0.4) 
Total 233 (100) 
Age 
Child (0-17 years) 16 (7) 
Adult (18+ years) 216 (93) 
Unknown 1 (0.4) 
Total 233 (100) 
n: number. 
Table 3. Distribution of incoming sample status of all presumptive TB patients, and smear microscopy 
results for new samples only. 
Category - n (%) 
Sample status 
New 211 (89) 
Follow-up 21 (9) 
Unknown 4 (2) 
Total 236 (100) 
Smear microscopy result 
Positive 32 (15) 
Negative 176 (83) 
Unknown 3 (1) 
Total 211 (100) 
n: number. 
Based on the classification criteria for molecular detection of MTB (see Methods), a total of 62/236 
(26%, 95% CI 21-32) samples were classified as MTB, and 24/236 (10%, 95% CI 7-15) were classified 
as MTBC/NTM. The remainder (150/236, 64%, 95% CI 57-69) were classified as negative for MTB. Of 
the 24 samples classified as MTBC/NTM, 22 had Cq values greater than 30 cycles (see Supplementary 
Material). 
3.2. Mutations Identified in MTB DNA 
Of the 240 sputum samples that were collected, 102 were assessed for resistance using the rpoB 
and katG primer sets. This included 87 samples classified as MTB (n = 62) or MTBC/NTM (n = 25), as 
well as 15 samples reactive for early runs of the IS6110 assay or a rpoB-based assay being tested 
externally to this study, but ultimately classified as negative. One MTBC/NTM sample was excluded 
from the results due to being a duplicate (see Methods). 
Amplicons were obtained from 53 of the 86 samples classified as MTB or MTBC/NTM. Overall, 
sequence data was obtained from one MTBC/NTM sample, while all other sequences were obtained 
from samples classified as MTB. 
rpoB sequencing was successful for 50 samples (Table 4). One sample classified as MTB based on 
qPCR did not match the H37Rv reference strain, and thus may not have been MTB. RIF resistance-
associated mutations were identified in five samples, as detailed in Table 4. These five samples were 
all classified as new (i.e., they were collected from people undergoing initial investigations for TB). 
Overall, 10% (5/50, 95% CI 4-21) of samples with rpoB sequencing were considered to be RIF-resistant, 
based on identification of a rpoB mutation that is known to confer drug resistance. 
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Table 4. Summary of sequencing results for the rpoB and katG amplicons, including nucleotide and 
codon mutations. 
rpoB Result katG Result Combined n 
WT WT WT 34 
WT N/A rpoB WT 5 








I480V (A1438G) katG WT 




N/A WT katG WT 1 
N/A P219L2 (C656T) katG mutant 1 
N/A 
A361V2 (C1082T) 












Not matched to ref N/A Not matched to ref 1 
Total   53 
n: number; N/A: not available (amplification or sequencing failed); ref: H37Rv reference genome;  
RIF-DR: rifampicin drug resistance; WT: wild-type (no mutations identified). 1 Codon mutation 
located within the RRDR of the rpoB gene, numbered according to the system based on MTB H37Rv 
[32]; 2 katG mutations with unknown association with drug resistance 
katG sequencing was successful for 47 samples, with mutations identified in two samples as 
described in Table 4. We were unable to confirm mutations in five samples because of discordant 
sequencing results in the forward and reverse strands. These included rpoB WT/F548L in one sample, 
katG WT/E261K in one sample, and katG WT/G279R in three samples (Table 4). These discordant 
results were not investigated further due to the high possibility of sequencing error, and as they have 
not previously been reported or associated with drug resistance their clinical significance is unknown. 
4. Discussion 
This study was undertaken on sputum samples collected in the rural Balimo region of PNG from 
presumptive TB patients. Molecular diagnostic techniques identified MTB in 26% to 36% (when 
including MTBC/NTM) of the samples. In our setting, classification as MTBC/NTM rather than MTB 
may have been due to a reduced ability to amplify the single copy senX3-regX3 gene, as a result of 
low MTB DNA concentration. As such, classification of MTBC/NTM is not considered to exclude 
MTB, but is simply a lack of confirmation. DR-TB was identified in samples collected at BDH, with 
RIF resistance-associated mutations identified in 10% (5/50, 95% CI 4-21) of the MTB or MTBC/NTM 
samples where rpoB sequencing was obtained.  
The rpoB S450L codon mutation, identified in five samples in this study, is the most frequently 
identified RIF resistance-associated mutation in the rpoB gene [33,34]. This mutation has been 
described previously in three studies from PNG, including in Western Province [5,8,13]. The rpoB 
I480V codon mutation, identified in one sample in this study, is much less common, and was first 
described in a study from Mexico, where it appeared alongside S450L as in our sample [35]. 
Interestingly, the same double amino acid change has recently been identified in a single clinical 
sample collected at Daru Hospital in Western Province, PNG [13]. However, the geographic origin of 
this patient was not stated. 
There is less certainty regarding the INH drug resistance association of the mutations identified 
in the katG gene. In this study S315T, the most common INH resistance-associated katG mutation, 
was not identified, despite being seen in other studies from PNG, including in Western Province 
[5,8,13]. However, katG mutations were identified in a number of sequences, and these should be 
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investigated further to confirm the possible presence of novel mutations, as well as for phenotypic 
DST. In addition, the inhA and ahpC genes, as well as other genes that have been associated with INH 
resistance, were not investigated. As a result, neither INH mono-resistance nor MDR-TB could be 
determined. Despite this finding, genotypic INH resistance should continue to be monitored, as 
several hundred different katG mutations have been documented in INH-resistant TB samples 
[19,36,37], with descriptions of new mutations likely to occur in the future. Additionally, inhA 
mutations have been identified in INH-resistant MTB strains elsewhere in PNG, including in Western 
Province [5,8,13]. 
For this study, repeat sequencing would be necessary to confirm mutations that have not 
previously been associated with drug resistance, and culture and DST would be required to confirm 
the phenotypic drug resistance status of rpoB and katG mutations identified, especially given some 
mutations may be seen in both drug-susceptible and drug-resistant isolates [19,36,38,39]. 
We identified RIF resistance-associated mutations in 10% (95% CI 4–21) of samples where rpoB 
sequencing was successful, indicating that DR-TB is already an established concern in the Middle Fly 
District. As described earlier, a high proportion of DR-TB has been described at Daru Hospital in the 
South Fly District of Western Province [4]. However, as Daru Hospital is the site for Xpert MTB/RIF 
testing of samples from across Western Province [27], clinical samples tested there will have 
originated from local residents as well as patients from elsewhere in the province, including Balimo. 
As a result, the proportion of DR-TB identified in Daru would be expected to be higher than the 
national average. The earlier study describing DR-TB in Daru, in combination with the results of our 
study undertaken in Balimo, highlight the geographic reach of DR-TB across much of Western 
Province.  
This was a small study, undertaken on samples collected on a passive case detection basis at 
BDH. The study was a laboratory-based analysis of samples collected as part of passive case detection 
activities at BDH, and the TB treatment history of patients was not recorded in the laboratory register. 
Furthermore, sequencing results were not obtained for 33 of the samples classified as MTB or 
MTBC/NTM. A larger study would be necessary to provide greater understanding of the 
epidemiology of DR-TB in the Balimo region. Further investigation would be particularly useful in 
understanding the treatment history and geographic distribution of DR-TB patients, and the genetic 
diversity of DR-TB strains. 
5. Conclusions 
This study has described the presence of RR-TB in the Balimo region, based on the identification 
of resistance-associated mutations in the rpoB gene. These findings extend our earlier research in 
Balimo, which has described a heavy burden of TB in the region, and highlighted the potential 
underdiagnosis of smear-negative pulmonary TB at BDH [24,26]. Identification of RR-TB in the 
Balimo region emphasises the need for further investigation of the DR-TB burden in the Middle Fly 
District of Western Province. Analysis of the TB treatment history of DR-TB patients would provide 
insight into the contribution of the various pathways to DR-TB in this region, that is, development 
versus transmission. Implementation in Balimo of a method such as the WHO-recommended Xpert 
MTB/RIF, which is capable of TB diagnosis and detection of RIF resistance, should be considered. 
Currently in Balimo, clinical samples from presumptive DR-TB patients must be sent to the provincial 
capital of Daru for Xpert MTB/RIF testing [27]. If the sample is positive, the patient must then travel 
to Daru to be commenced on DR-TB treatment, with completion under the supervision of an 
appropriately trained health worker [27]. Potential patient and provider challenges associated with 
this approach include delays in initiation of adequate treatment, active transmission of DR-TB to 
others, loss-to-follow-up while waiting for diagnostic results, and access challenges due to the long 
travel time to reach Daru. The presence of RIF resistance in this region distant from Daru emphasises 
the importance of understanding the heterogeneity of DR-TB across Western Province. Improving 
resources and facilities at BDH for local management of TB and DR-TB patients may reduce the strain 
placed on Daru Hospital, and play a role in the management of DR-TB patients in Western Province. 
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